Aspirin as prophylaxis against colorectal cancer
Article Abstract:
Several studies, including a 1995 study of nurses, indicate that regular use of aspirin reduces the risk of colorectal cancer. The mechanism of this risk reduction is not completely understood. Aspirin may inhibit abnormal cell growth by altering the metabolism of arachidonic acid and inhibiting platelet function. Aspirin inhibits the enzymes that convert arachidonic acid into prostaglandins and other eicosanoids from arachidonic acid. This inhibitory effect leads to increased synthesis of hydroxy acids that prevent multiplication of cells. In addition to aspirin, other nonsteroidal anti-inflammatory drugs reduce the size of polyps in the colon and the risk of colon cancer. Aspirin also inhibits the action of platelets, which normally release chemicals that promote cell growth. People with a risk of colorectal cancer should take one aspirin tablet every other day, as long as there are no distinct reasons to avoid the drug.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Ertapenem versus cefotetan prophylaxis in elective colorectal surgery
Article Abstract:
A randomized, double-blind trial assessed the efficacy and safety of antibiotic prophylaxis with ertapenem, as compared with cefotetan, in patients undergoing elective colorectal surgery. Results show ertapenem is more effective than cefotetan in the prevention of surgical-site infection in patients undergoing elective colorectal surgery but it may be associated with an increase in Clostridium difficile infection.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Celecoxib for the prevention of colorectal adenomatous polyps
Article Abstract:
Subjects who have a history of colonic adenomas and have undergone colonoscopy and polypectomy are treated for three years with a daily dose of celecoxib in order to examine its effectiveness in prevention of colorectal adenomatous polyps. Results reveal that a daily dose of celecoxib significantly reduces the occurrence of colorectal adenomas within three years of polypectomy.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Urinary catecholamines and metabolites in the immediate postoperative period following major surgery. Sudden death of a patient with primary hyperosinophilia colon tumours, and pulmonary emboli
- Abstracts: Tracing atrial fibrillation - 100 years. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants
- Abstracts: Integrin alphavbeta3 is a coreceptor for human cytomegalovirus. Detection of prions in blood
- Abstracts: Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis
- Abstracts: Comparison of intraocular pressure between normotensive and preeclamptic women in the peripartum period. Peripartum myocardial ischemia: A review of Canadian delieveries from 1970 to 1998